{
    "clinical_study": {
        "@rank": "153022", 
        "acronym": "RELZH12", 
        "arm_group": {
            "arm_group_label": "Methylnaltrexone", 
            "arm_group_type": "Experimental", 
            "description": "Pharmacokinetics of methylnaltrexone administered once daily"
        }, 
        "brief_summary": {
            "textblock": "-  Assessment of pharmacokinetic parameters of once daily subcutaneously administered\n           methylnaltrexone in 10 evaluable neurointensive care patients.\n\n        -  Quantification of methylnaltrexone passage through the blood-brain-barrier in\n           critically ill patients with severe cerebral affections.\n\n        -  Observation of laxation response after methylnaltrexone application and relation to\n           plasma concentrations of methylnaltrexone.\n\n        -  Assessing the safety of once daily administered methylnaltrexone in neurointensive care\n           patients.\n\n        -  Trial with medicinal product"
        }, 
        "brief_title": "Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Opioid Use, Unspecified With Other Opioid-induced Disorder", 
        "detailed_description": {
            "textblock": "After administration of methylnaltrexone s.c. multiple peripheral blood samples  and\n      additionally two liquor samples are drawn during a dose interval on day 1, 3, and 5 of drug\n      administration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  hospitalisation in the neurointensive care unit\n\n          -  deep sedation with sufentanil doses of = 40 mcg/h\n\n          -  male or female aged 18 years or older\n\n          -  females: negative pregnancy test\n\n          -  Ventricular drainage as part of needed therapeutic measures\n\n        Exclusion criteria:\n\n          -  History of hypersensitivity to methylnaltrexone (Relistor\u00ae)\n\n          -  confirmed or suspected obstructive ileus or factors possibly leading to intestinal\n             obstruction (e.g. an intestinal tumor)\n\n          -  increased risk for patients with localized or diffused reduction in structural\n             integrity of the gastrointestinal tract (e.g. peptic ulcer, acute diverticulitis)\n\n          -  severe hepatic insufficiency (Child-Pugh Class C)\n\n          -  renal impairment (glomerular filtration rate < 90 ml/min) with or without renal\n             replacement therapy\n\n          -  severe diarrhea despite high opioid dosing\n\n          -  participation in another study with an investigational drug within the 30 days\n             preceding and during the present study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01889290", 
            "org_study_id": "RELZH12"
        }, 
        "intervention": {
            "arm_group_label": "Methylnaltrexone", 
            "description": "Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl", 
            "intervention_name": "Methylnaltrexone", 
            "intervention_type": "Drug", 
            "other_name": "Relistor"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Methylnaltrexone", 
                "Naltrexone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "methylnaltrexone", 
            "opioid-antagonist", 
            "Obstipation", 
            "pharmacokinetics"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland"
                }, 
                "name": "Neurointensive Care Unit"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pharmacokinetics of Once Daily Subcutaneous Methylnaltrexone in Neurointensive Care Patients With High Dose Sufentanil Analgosedation", 
        "overall_contact": {
            "email": "natascia.corti@usz.ch", 
            "last_name": "Corti Natascia, MD"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Pharmacology and Toxicology", 
            "last_name": "Natascia Corti, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetic parameters of methylnaltrexone (Cmax, tmax, area under the curve, total clearance, halflife, accumulation ratio, renal clearance)", 
            "safety_issue": "Yes", 
            "time_frame": "5 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01889290"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}